drugset / Trial / NCT00055198

Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

NCT00055198

Phase 3 Terminated 75 enrolled Merck & Co., Inc.
Non-randomizedOpen-labelTreatment

Summary

The purpose of this study is to provide daptomycin, an antibiotic, to patients who are failing conventional therapy, or who cannot take approved antibiotics for one reason or another.

Timeline

Start
2002-12-19
Primary completion
2004-01-26
Completion
2004-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified